Leyden Labs is developing broad spectrum antivirals that target commonalities of viral families, potentially offering protection against known viruses as well as new viruses as they emerge. The company was founded in 2020 in response to the COVID-19 pandemic by Koenraad Wiedhaup, a former partner at McKinsey & Co, and three previous executives of Crucell, […]

View post to subscribe to site newsletter.

Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug targets. Instead of classic pharma, which takes a target of interest and develops drugs to bind that specific target, Unravel’s platform screens many drugs in parallel for their real-world impact […]

View post to subscribe to site newsletter.

Vernal Biosciences is aiming to democratize access to mRNA manufacturing technologies, with the goal of accelerating the clinical impact of mRNA as a foundational therapeutic modality. Vernal is focused on achieving and maintaining high purity throughout the scaling of all mRNA manufacturing processes for clients in the research and ultimately clinical stages. The company wants […]

View post to subscribe to site newsletter.